Table 1.

The benefits of different glucagon-like peptide-1 agonist molecules in the management of diabesity based on recent landmark clinical trials[103]

Drug molecule	Mean weight reduction in kg (95%CI)	Mean % HbA1c reduction (95%CI)	Follow-up period (yr)
Exenatide (weekly)	-1.27 (-1.4 to -1.13)	-0.53 (-0.57 to -0.50)	3.2
Liraglutide	-2.3 (-2.5 to -2.0)	-0.40 (-0.45 to -0.34)	3.8
Lixisenatide	-0.7 (-0.9 to -0.5)	-0.27 (-0.31 to -0.22)	2.1
Albiglutide	-0.83 (-1.06 to -0.60)	-0.52 (-0.58 to -0.45)	1.5
Dulaglutide	-1.46 (-1.67 to -1.25)	-0.61 (-0.65 to -0.58)	5.4
Semaglutide	-2.87 (-3.47 to –2.28) for 0.5 mg	-0.66 (-0.80 to – 0.52) for 0.5 mg	2.0
	-4.5 (-4.94 to -3.75) for 1 mg	-1.05 (-1.19 to -0.91) for 1 mg

HbA1C: Haemoglobin; CI: Confidence interval.